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bid modified Rankin Scale (pmRS) score, TE and allergic 
event that occurred during the hospital stay. All events were 
classified by 3 reviewers as being ‘related’, ‘probably related’, 
‘possibly related’, ‘unlikely related’ or ‘not related’ to treat-
ment with PCC. To identify factors associated with TEs, log-
rank analyses were applied.  Results: Two hundred and five 
patients were included. Median INR was 2.8 (interquartile 
range (IQR) 2.2–3.8) before and 1.3 (IQR 1.2–1.4) after PCC 
treatment and a median of 1,500 IU PCC (IQR 1,000–2,500) 
was administered. Nineteen TEs were observed (9.3%); none 
were classified ‘related’ but 9 were classified as ‘possibly’ or 
‘probably related’ to PCC infusion (4.4%). One allergic reac-
tion (0.5%), ‘unlikely related’ to PCC, was observed. In the 
whole cohort, PCC doses >2,000–3,000 IU, ICH volumes >40 
ml, National Institute of Health Stroke Scale values >10 and 
a pmRS >2 were associated with the development of TEs (p = 
0.031, p = 0.034, p = 0.050 and p = 0.036, respectively).  Con-
clusions: Overall, INR reversal with PCC appears safe. Though 
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 Abstract 
 Background: Prothrombin complex concentrates (PCCs) are 
frequently used to reverse the effect of vitamin K antagonists 
(VKAs) in patients with non-traumatic intracerebral hemor-
rhage (ICH). However, information on the rate of thrombo-
embolic events (TEs) and allergic events after PCC therapy in 
VKA-ICH patients is limited.  Methods: Consecutive VKA-ICH 
patients treated with PCC at our institution between 
 December 2004 and June 2014 were included into this ret-
rospective observational study. We recorded international 
normalized ratio (INR) values before and after PCC treat-
ment, baseline clinical characteristics including the premor-
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no clear relationship between higher PCC dosing and TEs 
was observed, PCC doses between >2,000 and 3,000 IU and 
higher morbidity at ICH onset were associated with TEs. 
Hence, individual titration of PCC to avoid exposure to un-
necessarily high doses using point-of-care devices should be 
prospectively explored.  © 2016 S. Karger AG, Basel 
 Introduction 
 Intracerebral hemorrhages (ICHs) represent the most 
feared complication of treatment with oral anticoagu-
lants  [1, 2] . About 10–18% of all ICH cases are associated 
with vitamin K antagonists (VKAs)  [3, 4] , and with up to 
54% of hematomas enlarging within the first hours after 
diagnosis, secondary hematoma growth in VKA-ICH is 
much more prevalent than in primary ICH (16%)  [5, 6] . 
Moreover, hematoma growth in VKA-ICH is often pro-
longed in time  [7] and mortality rates considerably ex-
ceed the rates of primary ICH (34 vs. up to 67%)  [1, 2, 
5–9] .
 To prevent hematoma enlargement and to reduce the 
associated risk of an unfavorable outcome including 
death  [10, 11] , guidelines recommend reversing the an-
ticoagulatory effect of VKA in ICH patients as fast as 
possible  [3, 10, 12–14] and current guidelines for VKA 
reversal in ICH recommend prothrombin complex con-
centrates (PCCs) combined with vitamin K over fresh 
frozen plasma (FFP)  [15] . PCC normalizes the interna-
tional normalized ratio (INR) more rapidly compared to 
FFP  [14, 16–18] , a finding that has recently been con-
firmed impressively in patients with VKA-ICH as well 
 [19] . Moreover, PCC does not require any serologic test-
ing before administration and necessary infusion vol-
umes are smaller compared to FFP  [11, 20, 21] . Impor-
tantly, fast INR normalization appears to be associated 
with smaller hematoma expansion in VKA-ICH  [19, 
22] .
 According to a large meta-analysis, the risk of 
 thromboembolic events (TEs) after PCC infusion is low 
( ∼ 1.8%), but indications for PCC treatment and sample 
sizes varied considerably between included studies  [23] .
 Data on TEs related to reversal treatment with PCC in 
patients with VKA-ICH are surprisingly rare. A recent 
study evaluating the prevalence of adverse events in a ho-
mogenous population with VKA-ICH reported 2 TEs in 
27 patients (7.4%) within the first 3 days after therapy 
with PCC and another 5 TEs (18.5%) within 3 months 
 [19] after PCC treatment.
 Here, we aimed to determine the rate of TE and allergic 
event after treatment with PCC in a large consecutive co-
hort of patients with VKA-ICH.
 Methods 
 Consecutive patients who were treated with PCC between 
 December 2004 and June 2014 at the Departments of Neurology and 
Neurosurgery, Heidelberg University Hospital, Germany, were in-
cluded into a prospective database. All patients with non-traumatic 
VKA-ICH entered the present observational analysis. Patients with 
ICH due to cerebral venous thrombosis, trauma, tumors, subarach-
noid hemorrhages, secondary ICH after thrombolysis or hemor-
rhagic transformation, non VKA-related coagulopathies and pa-
tients that were (co-)treated with recombinant factor VIIa or FFP 
were excluded. All neurosurgical interventions (e.g., hematoma 
evacuation, ventricular or hematoma drainage) were recorded. An-
alyzed data were obtained retrospectively from the patients’ charts.
 Standard procedures for all patients at admission encompassed 
a clinical examination, documentation of basic demographic vari-
ables and cardiovascular risk factors and brain imaging (CT or 
MRI). Stroke severity was assessed using the National Institute of 
Health Stroke Scale (NIHSS). Moreover, standardized laboratory 
testing, including a full blood count, glucose, electrolytes, urea, 
creatinine, prothrombin time and calculation of the INR was per-
formed at admission.
 In accordance with current guidelines  [10, 14] and local stan-
dardized procedures, VKA reversal with PCC was started as fast as 
possible after diagnosis of ICH in patients with an INR  ≥ 1.5 until 
an INR <1.5 was achieved and coagulation tests were repeated after 
the end of PCC infusion in all patients. The time between symptom 
onset and first CT or MRI, leading to the diagnosis of ICH, and the 
time between diagnosis of ICH and successful INR reversal 
(INR  < 1.5) were recorded.
 The following 4-factor PCC products (i.e., PCCs containing 
factors II, VII, IX and factor VII  [24] ) were used to reverse antico-
agulation: Beriplex P/N 500 ® (CSL Behring GmbH, Marburg, 
 Germany), Octaplex ® (Octapharma, Langenfeld, Germany) and 
PPSB-Human SD/Nano 600 ® (Octapharma, Langenfeld, 
 Germany; online suppl. table 1; for all online suppl. material, see 
www.karger.com/doi/10.1159/000448815). Dosing of PCC was 
based on INR values at admission and during follow-up measure-
ments. Dosing of PCC was performed upon the decision of the 
treating neurologist and based on the following local recommen-
dations: 1,000 IU PCC when the initial INR is >1.8; in case of an 
initial INR of  ≥ 1.5 and <1.8, 500 IU; INR retesting after 10 min; if 
the INR remains >1.8, administration of another 500 IU and INR 
retesting until an INR <1.5 is achieved.
 Additional administration of vitamin K to avoid VKA-associ-
ated INR rebound after reversal treatment  [10] and start of low 
molecular weight heparin (LMWH) for prevention of venous 
thromboembolism during the first 48 h after admission were per-
formed upon the decision of the treating physician.
 TE and Allergic Event 
 All TEs as well as allergic and anaphylactic reactions that oc-
curred during treatment in our hospital were identified. In order 
to diagnose acute myocardial infarction (MI), clinical symptoms, 
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electrocardiographic changes, troponin T elevations (>50 pg/ml) 
and results of cardiac catheterization were taken into consider-
ation  [25] . Deep vein thrombosis was diagnosed by typical clinical 
signs and/or imaging of the venous system. To diagnose pulmo-
nary embolism (PE), clinical symptoms, vital parameters, ECG 
changes, blood gas analyses and imaging results were taken into 
consideration  [26] . Ischemic strokes were diagnosed by clinical 
symptoms and the results of brain imaging  [27] .
 Allergic and anaphylactic reactions were diagnosed in case of 
new skin exanthemas, rush, pruritus, oro-lingual edema or sudden 
and otherwise unexplained abnormalities of the cardiorespiratory 
system  [28] .
 All events were reviewed by 3 reviewers (M.L., O.J.M. and T.R.) 
following the World Health Organization Collaborating Centre 
for International Drug Monitoring (Uppsala Monitoring Center) 
causality assessment system  [29] . All events were subsequently cat-
egorized in consensus by the reviewers as being ‘related’, ‘probably 
related’, ‘possibly related’, ‘unlikely related’ or ‘not related’ to treat-
ment with PCC.
 ICH Enlargement and Clinical Outcome 
 ICH was classified according to its location into lobar, deep and 
infratentorial  [30] . To quantify intraventricular hemorrhage, the 
modified Graeb score was applied  [31] . Follow-up brain imaging 
(CT or MRI) to assess hematoma enlargement was conducted 
 20–36 h after the initial diagnosis or earlier in case of clinical dete-
rioration. As previously described, planimetric volumetry was per-
formed by the ABC/2 or, in case of irregularly shaped hematomas, 
by the ABC/3 formula  [32, 33] . Substantial hematoma growth was 
defined as hematoma enlargement of  ≥ 33.3% or 6 ml  [34] between 
initial and follow-up brain imaging. The modified Rankin Scale 
(mRS) was used to report the functional status before ICH premor-
bid mRS (pmRS) and at discharge. Functional independence post 
ICH was defined in accordance with previous reports  [19] as mRS 
values of 0–3.
 The independent Ethics Committee of the medical faculty of 
the Heidelberg University approved the study, and the manuscript 
was developed according to the STROBE guidelines for reporting 
observational studies  [35] .
 Statistical Analysis 
 Most descriptive data are presented in relative frequencies, or-
dinal and continuous data as medians and interquartile ranges 
(IQRs). To test for normal distribution, the Kolmogorov–Smirnov 
test was applied. Depending on the scale level of variables, we used 
the Mann–Whitney U test for continuous, but not normally dis-
tributed variables and the chi-square test for categorical variables 
to explore differences between groups with regard to the presence 
of TEs and ICH enlargement. To test associations between INR 
values and ICH enlargement, Spearman correlations were applied. 
The time between symptom onset and diagnosis of ICH was cat-
egorized into the following intervals: <2, 2–4, 4–6, 7–12, 13–24 
and >24 h. Based on a previous approach  [36] , ICH volume at ad-
mission was categorized into 6 groups (<20 and  ≥ 20 ml, <30 and 
 ≥ 30 ml, <40 and  ≥ 40 ml, <50 and  ≥ 50 ml, <60 and  ≥ 60 ml, <70 and 
 ≥ 70 ml). To investigate associations of clinical characteristics and 
therapeutic variables on TEs, Kaplan–Meier and log rank analyses 
were used. To compare TE-distributions of different subgroups 
(e.g., dependent on PCC dosage, stroke severity), we used the log 
rank test and Kaplan–Meier plots to visualize the estimated sur-
vival curves. To distinguish between severe and light to moderate 
pre-stroke disability and stroke severity, pmRS and NIHSS values 
were dichotomized (pmRS: 0–2 and 3–5; NIHSS: 0–10 and 11–42) 
 [37] . PCC dosages were included in Kaplan–Meier plots and log 
rank tests to test for dose-dependent incidences of TEs by using 
the following groups:  ≤ 1,000 vs. >1,000 IU,  ≤ 2,000 vs. >2,000 IU, 
 ≤ 3,000 vs. >3,000 IU and  ≤ 4,000 vs. >4,000 IU. A p value of  ≤ 0.05 
was considered statistically significant. Data analysis was per-
formed using the Statistical Package for Social Sciences (SPSS) 22.0 
for Windows (IBM, Armonk, USA).
 Results 
 Patient and ICH Characteristics 
 Overall, we included 205 patients (c.f. online suppl. 
fig. 1). Basic demographic variables, cardiovascular risk 
factors and indications for oral anticoagulation are sum-
marized in  table 1 . The median age was 75 years (IQR 69–
Table 1.  Baseline and treatment characteristics of included patients 
(n = 205)
Clinical characteristics and risk factors
Age, years, median (IQR) 75.0 (69–80)
Male sex, n (%) 133 (64.6)
NIHSS at admission, median (IQR) 13 (6–22)
pmRS, median (IQR) 1 (0–2)
Arterial hypertension, n (%) 189 (91.7)
Hypercholesterolemia, n (%) 62 (30.1)
Statin use, n (%) 52 (25.2)
Diabetes, n (%) 61 (29.6)
History of ICH, n (%) 13 (6.3)
History of TIA/ischemic stroke, n (%) 37 (18.0)
VKA indications, n (%)
Atrial fibrillation 142 (69.3)
Mechanical heart valve 19 (9.3)
Deep vein thrombosis 19 (9.3)
PE 11 (5.4)
Cardiomyopathy 4 (2.0)
Others/unknown 8 (3.9)
Symptom onset to diagnosis of ICH, h, n (%)
≤2 56 (27.3)
>2–4 22 (10.7)
>4–6 39 (19.0)
>6–12 30 (14.6)
>12–24 21 (10.2)
>24 37 (18.0)
PCC dose, IU, n (%)
≤1,000 61 (29.8)
>1,000–2,000 82 (40.0)
>2,000–3,000 40 (19.5)
>3,000–4,000 17 (8.3)
>4,000 5 (2.4)
 TIA = Transient ischemic attack.
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80), 64.6% of patients were male and the median NIHSS 
at admission was 13 (IQR 6–22). The most common rea-
son for oral anticoagulation was atrial fibrillation (69.3%), 
followed by deep vein thrombosis (9.3%) and mechanical 
heart valves (9.3%;  table 1 ). Patients were hospitalized at 
our center for a median of 6 days (IQR 3–11).
 Most hematomas were localized in deep brain struc-
tures (n = 99; 48.3%). Lobar bleeds were observed in 72 
patients (35.1%) and 28 (13.7%) suffered infratentorial 
hemorrhages. Pure intraventricular hemorrhages were 
diagnosed in 6 patients (2.9%).
 INR Reversal 
 At admission, the median INR was 2.8 (IQR 2.2–3.8). 
A median dose of 1,500 IU PCC (IQR 1,000–2,500) was 
administered. One hundred and thirty-nine minutes after 
ICH diagnosis (median; IQR 89–241), the INR was re-
versed (INR <1.5) and a median INR of 1.3 was observed 
after completion of PCC treatment (IQR 1.2–1.4; p  < 
0.001).
 Within 48 h after admission, 172 patients (83.9%) re-
ceived LMWH for prevention of venous thromboembo-
lism.
 TE and Allergic Event 
 In total, 19 TEs (9.3%) and 1 allergic event (0.5%) were 
identified among the 205 patients (c.f.  fig.  1 ). Ischemic 
strokes represented the most common type of TEs (7 of 19; 
36.8%), followed by MI (6 of 19, 31.6%), PE (3 of 19, 15.8%) 
and deep vein thrombosis (3 of 19, 15.8%). All ischemic 
strokes and MIs were observed in patients with AF, and 2 
of 3 cases of PEs (66.7%) occurred in patients who were 
treated with VKA due to former deep vein thrombosis.
 Importantly, none of the events was considered ‘re-
lated’ to treatment with PCC, but 2 of 19 TEs (10.5%) 
were categorized ‘probably related’ to the preceding PCC 
treatment (2 ischemic strokes), and 7 of 19 events (36.8%) 
were judged ‘possibly related’ to treatment with PCC (2 
ischemic strokes, 2 MIs, 2 PEs and 1 deep vein thrombo-
sis). All other events were rated as either ‘unlikely related’ 
(7 of 19; 36.8%) or ‘not related’ (3 of 19; 15.8%) to PCC 
treatment ( fig. 1 ).
 The observed allergic reaction was assessed ‘unlikely 
related’ to treatment with PCC; it followed cerebral angi-
ography with iodine-containing contrast medium 4 days 
after PCC infusion.
 Factors Associated with Any TE 
 Associations between demographic factors, clinical pa-
rameters and treatment-related factors with TEs that were 
observed are summarized in  table 2 . Log rank analyses re-
vealed that factors associated with TEs (n = 19) were PCC 
dosages between >2,000 and 3,000 IU (p = 0.031), severe 
strokes at admission (NIHSS scores >10; p = 0.050) and a 
pmRS of 3–5 (p = 0.016;  table 2 ). Kaplan–Meier plots for 
PCC dosages and dichotomized NIHSS values are given in 
 figure 2 . Because the assumption of proportional hazards 
was not fulfilled, Cox regression was not performed.
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 Clinical Outcome and Association with TEs 
 In-hospital mortality was 27.8% (n = 57), and 22.0% 
(n = 45/205) of patients were functionally independent at 
discharge (mRS 0–3). Expectedly, mortality was higher in 
patients with hematoma growth (46.9%) compared to 
those without (13.4%; p < 0.001). Mortality rates did not 
differ between patients with and without TEs (40 vs. 
26.8%; p = 0.190). Moreover, no difference with regard to 
the rate of functional independency was observed be-
tween patients with and without TEs (15.8 and 22.4% re-
spectively; p = 0.530).
 Discussion 
 The major findings of this study are that (1) TEs after 
PCC treatment were observed in 9.3% of patients but 
none were classified as ‘related’ to the treatment with 
PCC. (2) None of the TEs were classified as ‘related’ but 
TEs were considered ‘possibly’ or ‘probably related’ to 
treatment with PCC in 4.4% of patients. (3) In patients 
with PCC, dosages between >2,000 up to 3,000 IU TEs 
compared to lower dosages were observed. (4) Worse 
premorbid status and higher stroke severity were associ-
ated with TEs.
 Faster restoration of coagulation and lower infusion 
volumes represent clear advantages of PCC compared to 
FFP in anticoagulation reversal in VKA-ICH patients 
 [10, 11, 14, 16, 17, 19, 21] . Hence, PCC are widely used in 
this indication  [22, 38] . However, despite the fact that 
PCC is frequently used in clinical routine, data on PCC-
related thromboembolic complications in patients with 
 VKA-ICH are still limited  [19, 39] .
 In anticoagulation reversal with PCC not being limited 
to VKA-ICH patients, thromboembolic complications 
associated to PCC administration have been reported in 
1.8% in a meta-analysis and in 0.0–7.3%  [23, 39–43] 
among observational cohort studies and randomized-
controlled trials that included patients with VKA-related 
bleedings or prior to urgent surgical procedures. Evaluat-
ing specifically VKA-ICH patients, a retrospective study 
with 30 VKA-ICH patients treated with PCC reported a 
TE rate of 10%  [40] . In the Intracranial Hemorrhage Re-
lated to VKA trial  [19], 7.4% of patients within the PCC 
group (n = 27) suffered TEs during the first 3 days after 
treatment, and in 29.2% of patients, TEs were observed 
during the observational period of 90 days  [19] . On the 
other hand, in ICH patients who did not have anticoagu-
lation, venous thromboembolism has been reported in 
1.9–19.8%  [44–47] .
 We observed TEs in 9.3% of patients during the acute 
hospital stay. All the more, no event was classified ‘relat-
ed’ to treatment with PCC, suggesting that the use of PCC 
for VKA reversal in ICH is sufficiently safe with respect 
to TEs. Explanations for the higher rate of TEs in 
 VKA-ICH  [19, 40] compared to inhomogeneous popula-
tions that received PCC due to different indications re-
main speculative. ICH patients are often multimorbid 
 [47] and frequently immobilized  [48] during the hospital 
stay, which comprises a high risk for thromboembolism. 
Moreover, uniform procedures to report TEs do not exist 
and causal assessment of TEs related to treatment with 
PCC is usually challenging. Patients with an indication 
for anticoagulation are already at an increased risk for 
systemic thromboembolisms and other comorbidities 
impede a clear attribution of TEs to PCC, for instance in 
case of MIs after PCC treatment in patients with coronary 
heart disease, and it remains unknown until when TEs 
caused by PCC treatment itself may occur. Moreover, the 
Table 2.  Association of patients’ and treatment characteristics with 
TEs (n = 19) in log rank analysis
Characteristic p value
Demographic data
Age (≤75, >75 years) 0.678
Sex (female, male) 0.120
pmRS (0–2, 3–5) 0.036
Cardiovascular risk factors
Arterial hypertension (present/absent) 0.479
Diabetes (present/absent) 0.520
Hypercholesterolemia (present/absent) 0.057
Clinical parameters
NIHSS (≤10, >10) 0.050 
Hemorrhage volume (<20, ≥20 ml) 0.183
Hemorrhage volume (<30, ≥30 ml) 0.312
Hemorrhage volume (<40, ≥40 ml) 0.034
Hemorrhage volume (<50, ≥50 ml) 0.013
Hemorrhage volume (<60, ≥60 ml) 0.109
Hemorrhage volume (<70, ≥70 ml) 0.036
Ventricular hemorrhage (present/absent) 0.103
ICH enlargement (present/absent) 0.406
Neurosurgical intervention (present/absent) 0.103
LMWH within 48 h (present/absent) 0.922
Hemostatic treatment
PCC dose (≤1,000, >1,000 IU) 0.325
PCC dose (≤2,000, >2,000 IU) 0.031
PCC dose (≤3,000, >3,000 IU) 0.378
PCC dose (≤4,000, >4,000 IU) 0.451
Functional outcome
mRS (0–3, 4–6) 0.169
p values ≤0.05 are shown in bold.
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assessment of TEs and their causal relation to PCC ther-
apy differed among studies  [15–17, 21, 38, 41, 42] and 
observation times to evaluate TEs after PCC administra-
tion varied considerably (2–90 days)  [16, 17, 19, 21, 38, 
39, 43, 44] . Hence, it can be assumed, that these factors 
contribute to considerable differences of reported TEs af-
ter PCC treatment.
 According to our results, PCC doses between >2,000 
and 3,000 IU were associated with TEs but a clear rela-
tionship between higher PCC dosing and development of 
TEs was not observed, as in the groups with even higher 
PCC doses, TEs were not detected more frequently. Rea-
sons for this observation may be the small absolute num-
ber of TEs and the comparatively small number of pa-
tients who received particularly very high amounts of 
PCC (>3,000 IU PCC: 22 vs. 183 patients receiving <3,000 
IU PCC). Nonetheless, our results suggest that higher 
PCC doses might be a risk for the development of TEs. 
Individual titration of PCC  [49] to avoid exposure to un-
necessarily high doses using point-of-care devices at the 
bedside is a potential option.
 Our findings suggest that ICH patients with higher 
disease severity (i.e., NIHSS values >10 and hemor-
rhage volume  ≥ 40 ml) and a restricted premorbid func-
tional status (pmRS >2), indicating multimorbidity, 
more often suffered TEs after treatment with PCC. 
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 Fig. 2. Plots of the Kaplan–Meier estimator.  a Comparing the de-
velopment of TEs in patients with PCC doses >3,000 vs.  ≤ 3,000 IU; 
log rank test p = 0.031.  b Comparing the development of TEs in 
patients with NIHSS scores >10 vs.  ≤ 10; p = 0.050.  c Comparing 
the development of TEs in patients with an ICH volume  ≥ 40 vs. 
<40 ml; p = 0.034.  d Comparing the development of TEs in patients 
with pmRS scores >2 vs. 0–2 on development of TEs; p = 0.036. 
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Hence, an approach of titrating PCC individually may 
be most beneficial particularly in these critically ill pa-
tients. On the other hand, the optimal procedure to pre-
vent thromboembolism in this subgroup of ICH pa-
tients prone to develop TEs during the course of the 
hospital stay after INR reversal remains unknown  [47, 
50] . When caring for these patients, one should be aware 
of higher incidences of TEs in more severely affected 
VKA-ICH patients. Intermittent pneumatic compres-
sion of lower limbs or low-dose LMWH or unfraction-
ated heparin, respectively, is currently recommended to 
prevent TEs  [14] . Nevertheless, optimal measures to 
prevent TEs in this important subgroup of ICH patients 
remain unknown and should be evaluated in future 
studies.
 The lack of a control group and the small number of 
TEs are limiting our results, and because adjustment for 
multiplicity was not performed, our results can only be 
interpreted descriptively. Late-onset TEs may have been 
underestimated because of the limited time of observa-
tion (median 6 days). Due to the retrospective character-
istic, no standardized follow-up was performed. More-
over, body weight was not measured and no standardized 
ultrasound screening to detect clinical silent deep vein 
thrombosis was performed. However, we evaluated a 
large, homogenous group of patients with VKA-associat-
ed non-traumatic ICH and categorized all TE and allergic 
event carefully.
 To conclude, reversal treatment in VKA-ICH with 
PCC appears safe. Though no clear relationship between 
higher PCC dosing and development of TEs was ob-
served, PCC doses between >2,000 and 3,000 IU and 
higher morbidity at ICH onset was associated with TEs. 
Hence, individual titration of PCC to avoid exposure to 
unnecessarily high doses using point-of-care devices 
should be prospectively explored.
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